SRRK Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Scholar Rock Holding's net margin of 32.59%. Scholar Rock Holding's return on equity of -- beat Eli Lilly and's return on equity of 80.24%.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 64.5%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 28.06%. Given that Scholar Rock Holding has higher upside potential than Eli Lilly and, analysts believe Scholar Rock Holding is more attractive than Eli Lilly and.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.68% to investors and pays a quarterly dividend of $1.50 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Scholar Rock Holding quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Scholar Rock Holding's net income of -$66.5M is lower than Eli Lilly and's net income of $4.4B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 67.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 64.80x versus 15.84x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Scholar Rock Holding's net margin of 23.96%. Scholar Rock Holding's return on equity of -- beat Merck &'s return on equity of 40.25%.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 64.5%. On the other hand Merck & has an analysts' consensus of $112.07 which suggests that it could grow by 29.72%. Given that Scholar Rock Holding has higher upside potential than Merck &, analysts believe Scholar Rock Holding is more attractive than Merck &.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Merck & has a beta of 0.401, suggesting its less volatile than the S&P 500 by 59.879%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 3.66% to investors and pays a quarterly dividend of $0.81 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Scholar Rock Holding quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.6B. Scholar Rock Holding's net income of -$66.5M is lower than Merck &'s net income of $3.7B. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Merck &'s PE ratio is 12.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 64.80x versus 3.42x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Terns Pharmaceuticals has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Terns Pharmaceuticals's return on equity of --.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 64.5%. On the other hand Terns Pharmaceuticals has an analysts' consensus of $19.06 which suggests that it could grow by 718.13%. Given that Terns Pharmaceuticals has higher upside potential than Scholar Rock Holding, analysts believe Terns Pharmaceuticals is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Terns Pharmaceuticals has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Terns Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Terns Pharmaceuticals pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Terns Pharmaceuticals quarterly revenues of --. Scholar Rock Holding's net income of -$66.5M is lower than Terns Pharmaceuticals's net income of -$21.8M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Terns Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 64.80x versus -- for Terns Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -- compared to Scholar Rock Holding's net margin of --. Scholar Rock Holding's return on equity of -- beat Viking Therapeutics's return on equity of --.

Scholar Rock Holding has a consensus price target of $50.50, signalling upside risk potential of 64.5%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 309.97%. Given that Viking Therapeutics has higher upside potential than Scholar Rock Holding, analysts believe Viking Therapeutics is more attractive than Scholar Rock Holding.

Scholar Rock Holding has a beta of 0.565, which suggesting that the stock is 43.511% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Scholar Rock Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Scholar Rock Holding pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Scholar Rock Holding quarterly revenues are --, which are smaller than Viking Therapeutics quarterly revenues of --. Scholar Rock Holding's net income of -$66.5M is lower than Viking Therapeutics's net income of -$35.4M. Notably, Scholar Rock Holding's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Scholar Rock Holding is 64.80x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.